oral semaglutide cardiovascular outcomes soul trial results 2024 2025 A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link soul trial oral semaglutide cardiovascular

Currently: BPC-157 is not FDA-approved There are no standardized treatment guidelines Long-term human safety data is lacking Large randomized clinical trials have not been completed Optimal dosing protocols have not been established Because most published research comes from animal studies, scientists cannot yet determine whether the same effects occur in humans

Hany Demian, MD, a board-certified physician in pain management and aesthetic medicine and the CEO and founder of Praesentia Health and BioSpine Institute in Fort Myers, Florida

Wang Y, Ni Z, Li K

GLUTHIC is an antioxidant supplementation required in daily life, and it is derived from a naturally-occurring tripeptide called L-Glutathione, which is renowned for its ability to support cell defense and keep skin protected from oxidative stress

Among the participants, 534 received semaglutide, and 266 received a placebo

Dosage and Protocol Consistency How the peptide is administered matters